Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study
Authors
Keywords
NSCLC, Predictive molecular pathology, NGS, Single-gene test, Cost
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 169, Issue -, Pages 103525
Publisher
Elsevier BV
Online
2021-11-21
DOI
10.1016/j.critrevonc.2021.103525
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective
- (2021) Umberto Malapelle et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Next generation sequencing in cytology
- (2021) Pasquale Pisapia et al. CYTOPATHOLOGY
- The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
- (2021) Keith M. Kerr et al. LUNG CANCER
- How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review
- (2021) Gabriel Fernando Torres et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
- (2021) Christian Rolfo et al. Journal of Thoracic Oncology
- New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)
- (2020) Alessandro Russo et al. Current Oncology Reports
- Precision medicine in non-small cell lung cancer: Current applications and future directions
- (2020) Soo-Ryum Yang et al. SEMINARS IN CANCER BIOLOGY
- Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients
- (2020) Luciene Schluckebier et al. BMC CANCER
- Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
- (2020) Shumei Kato et al. Nature Communications
- Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
- (2020) John H. Strickler et al. CLINICAL CANCER RESEARCH
- Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
- (2020) Evgeny N. Imyanitov et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
- (2019) Natasha B. Leighl et al. CLINICAL CANCER RESEARCH
- P2.04-54 Characteristic of MSI-H Lung Cancer Patients Identified with Targeted Next-Generation Sequencing
- (2019) W. Lin et al. Journal of Thoracic Oncology
- Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization
- (2019) Luna Kadouri et al. LUNG CANCER
- Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
- (2019) Aaron C. Tan et al. LUNG CANCER
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study
- (2018) Patricia Marino et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
- (2018) Gregory P. Kalemkerian et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
- (2018) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Lung Cancer Biomarkers
- (2017) Pamela Villalobos et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis
- (2016) Linda M. Sabatini et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer
- (2010) F. R. Hirsch et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More